This inventor holds 1 USPTO granted patent. Top assignees: Astex Therapeutics Limited, Taiho Pharmaceutical. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 126 
1 out of 5 Years Active: 2026
Title: Tetsuya Abe: Inventor in Cancer Research
Introduction
Tetsuya Abe is an inventor associated with Tsukuba, Japan. His work includes a patent application concerning a combination therapy for cancer, and his professional affiliations include Taiho Pharmaceutical and Astex Therapeutics Limited. The supplied information lists 1 patent.
Latest Patents
Abe is named in the patent titled “Anticancer Combination Therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide Inhibitor of KRAS-G12C.” The disclosed method treats cancer by administering a therapeutically effective amount of a Formula (I) compound, or a pharmaceutically acceptable salt of that compound, together with a therapeutically effective amount of an additional anticancer agent. The compound’s structural variables are defined in the patent disclosure.
Career Highlights
The information provided associates Abe with Taiho Pharmaceutical and Astex Therapeutics Limited. The patent’s focus on combination treatment involving a KRAS-G12C inhibitor reflects research directed toward cancer therapy.
Collaborations
Abe’s listed coworkers include Yoko Nakatsuru and Hiroshi Sootome. Their names are provided as professional associations, though specific roles in the patent are not detailed here.
Conclusion
Tetsuya Abe is associated with cancer-treatment innovation through a patent describing combination therapy that includes a KRAS-G12C inhibitor.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile